Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experimental corneal allograft rejection.

Bryan M Gebhardt1, Weiyun Shi

  • 1Lions Eye Research Laboratories, LSU Eye Center, LSU Health Sciences Center, New Orleans, LA 70112-2234, USA. BGEBHA@LSUHSC.EDU

Immunologic Research
|March 1, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correlation between retinal defocus distribution and axial growth in myopic children wearing orthokeratology lenses.

BMC ophthalmology·2026
Same author

Comparative analysis of corneal biomechanical parameters in pterygium using scheimpflug technology.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026
Same author

Bioinspired Tissue Transparency: Achieving Sclera-to-Cornea Transplantation.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Antibiotic nanozyme hydrogel depot for single-injection MDR bacterial keratitis therapy <i>via</i> localized antibacterial, pro-healing and corneal reinforcement.

Materials today. Bio·2026
Same author

Mitochondria in corneal physiology and pathology: A mechanistic perspective.

Progress in retinal and eye research·2025
Same author

Growth factor receptor-bound protein 2-mediated corneal epithelial injury drives depression-associated dry eye disease.

Biochemical pharmacology·2025
Same journal

Emapalumab plus conventional therapy with or without ruxolitinib for pediatric hemophagocytic lymphohistiocytosis: a single center retrospective study.

Immunologic research·2026
Same journal

Immunological spectrum in patients with thymoma: beyond good syndrome.

Immunologic research·2026
Same journal

Microbiome immune crosstalk in Sjögren's syndrome: mechanistic insights and translational perspectives.

Immunologic research·2026
Same journal

Immune checkpoint inhibitor-induced myasthenia gravis and myocarditis: a fatal immune-related adverse event.

Immunologic research·2026
Same journal

TRIM28 and TRIM32: multifaceted regulators of innate immunity and antiviral defence.

Immunologic research·2026
Same journal

Decoding PANoptosis: Crosstalk of cell death pathways in immunity and inflammation.

Immunologic research·2026
See all related articles

Corneal allograft rejection is a cell-mediated process. Preventing inflammation and vascularization with immunomodulators and antiangiogenic agents shows promise for successful corneal transplantation.

Area of Science:

  • Immunology
  • Ophthalmology
  • Transplantation Science

Background:

  • Corneal avascularity grants immunologic privilege, but transplantation trauma compromises this.
  • Corneal allografts are susceptible to immune rejection due to inflammation and neovascularization post-transplant.
  • Corneal cells exhibit lower antigenicity compared to other tissues.

Purpose of the Study:

  • To review major findings on corneal allograft rejection in experimental animals.
  • To understand the mechanisms underlying immune-mediated corneal allograft rejection.
  • To explore strategies for preventing corneal allograft rejection.

Main Methods:

  • Review of experimental animal studies (rabbits, rats, mice) on corneal allograft rejection.
  • Analysis of the immunologic and cellular mechanisms involved in rejection.

Related Experiment Videos

  • Evaluation of therapeutic strategies for prevention.

    • Main Results:

    • Corneal allograft rejection is a T-lymphocyte-mediated process targeting major histocompatibility complex antigens.
    • CD4+ T helper cells and CD8+ cytotoxic cells are involved in the rejection response.
    • Inflammation and neovascularization are key factors predisposing grafts to rejection.

    Conclusions:

    • Preventing corneal allograft rejection requires topical compounds that inhibit inflammation, vascularization, and T-lymphocyte activation.
    • Immunomodulators like blocking antibodies and CTLA4-Ig have shown progress.
    • Combinations of antiangiogenic agents and immunomodulators offer significant potential for clinical application.